Moleculin (NASDAQ: $MBRX) is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant cancers and viruses.
South Korea's decision to grant a new patent extends Annamycin protection into another key Asia-Pacific market, reinforcing $MBRX's multi-layered patent portfolio spanning more than 20 jurisdictions as the Company's pivotal Ph. 3 MIRACLE trial advances. https://t.co/TzCfnHXbyI
Moleculin today announced that South Korea’s Ministry of Intellectual Property has issued a decision to grant a patent covering the Company’s method of reconstituting liposomal Annamycin (also known as naxtarubicin). Read more: https://t.co/TzCfnHXbyI $MBRX
"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and CEO. Read more: https://t.co/Nllq39rHWm $MBRX
At Moleculin, we are focused on advancing innovative therapies for hard-to-treat cancers.
Our clinical pipeline is led by Annamycin, currently being evaluated for relapsed or refractory acute myeloid leukemia.
$MBRX #Oncology#AML#CancerResearch
Moleculin reported on Friday its Q3 financial results and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Ph. 2/3 MIRACLE trial evaluating Annamycin in R/R AML. https://t.co/Nllq39rHWm $MBRX
“Securing this patent in Australia represents another step in our efforts to build a strong international intellectual property position around Annamycin,” said Walter Klemp, Chairman and Moleculin CEO. Read more: https://t.co/z99K07uaUq $MBRX
Moleculin today announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology. https://t.co/z99K07uaUq $MBRX
Walter Klemp, Chairman, President and CEO of Moleculin, comments on preclinical data showing Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer models beyond that achieved with either agent alone. Read more: https://t.co/DeEkslTapD $MBRX
Annamycin achieves substantially higher pancreatic tissue exposure than doxorubicin, offering a potential explanation for why topoisomerase II, a validated target in pancreatic cancer, has never been successfully drugged there. Read more: https://t.co/DeEkslTapD $MBRX
Inhibition of CD8+ T cells shortened survival in Annamycin-treated mice, demonstrating that the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander. Read more: https://t.co/DeEkslTapD $MBRX
Waldemar Priebe, PhD, of @UTMDAnderson, will present new preclinical findings on Annamycin in an oral presentation today at the 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care, organized by @MoffittNews in Tampa, FL. https://t.co/DeEkslTapD $MBRX
Moleculin announced new preclinical data showing that its lead drug candidate, Annamycin (naxtarubicin), combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond that achieved with either agent alone. https://t.co/DeEkslTapD $MBRX
$MBRX's lead candidate, Annamycin, is a re-engineered anthracycline designed to overcome multidrug resistance and reduce the cardiotoxicity associated with conventional anthracyclines.
Learn more: https://t.co/vM8nM3XWyN
#AML#Oncology
Moleculin’s first interim results from its pivotal Phase 2/3 trial showed complete remission rates of 43% and 36% in the Annamycin arms, compared to 12% with placebo in patients with relapsed or refractory AML. Read more ahead of #ASH26: https://t.co/SotR94pPrp $MBRX
Walter Klemp, Chairman and CEO of Moleculin, discusses encouraging first interim results from the pivotal Phase 2/3 trial in patients with R/R AML, which will be presented at #ASH26.
For more details about the upcoming presentation: https://t.co/SotR94pPrp $MBRX
Moleculin today announced that an abstract highlighting data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 @ASH_hematology Annual Meeting, taking place December 12-15, 2026 in NOLA. For details: https://t.co/SotR94pPrp #ASH26 $MBRX
“Reaching the completion of dosing in Part A represents another important step toward our planned Q1 2027 comprehensive n=90 data readout,” said Walter Klemp, Chairman and CEO of Moleculin. Read more on the Phase 2/3 MIRACLE trial: https://t.co/kg3Dky476c $MBRX
Moleculin’s completion of dosing in Part A marks an important milestone in its Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML). Read more: https://t.co/kg3Dky476c $MBRX
Fully treated, randomized, double-blind n=90 Part A population sets up Annamycin dose selection for Part B, with balanced representation of AML patients who failed 7+3 chemotherapy and venetoclax-based regimens. Read more on the recent milestone: https://t.co/kg3Dky476c $MBRX
Moleculin today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with R/R AML. Read more: https://t.co/kg3Dky476c $MBRX